Use of saliva for monitoring oxcarbazepine therapy in epileptic patients

Abstract

The utility of saliva sampling in monitoring oxcarbazepine therapy has been assessed in 17 epileptic outpatients treated with a mean dose 22.7 mg/kg/d for 19–411 days, i. e. at steady-state. Blood was collected before the morning dose measurement of the plasma 10-OH-carbazepine concentration and determination of the protein bound fraction. Immediately after… (More)
DOI: 10.1007/BF00870993

Topics

2 Figures and Tables

Cite this paper

@article{Klitgaard1986UseOS, title={Use of saliva for monitoring oxcarbazepine therapy in epileptic patients}, author={Niels Anders Klitgaard and Ove Kristensen}, journal={European Journal of Clinical Pharmacology}, year={1986}, volume={31}, pages={91-94} }